Recent

% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

trendbase 68 posts  |  Last Activity: Feb 2, 2016 7:00 AM Member since: Nov 27, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Sanofi launches hunt for Zika vaccine

    by trendnotyourfriend Feb 2, 2016 4:28 AM
    trendbase trendbase Feb 2, 2016 7:00 AM Flag

    They already have a full schedule. Agenus needs to focus on their present pipeline. They are working on partnerships with there AutoSynVax program. They already have Preclinical proof-of-concept studies and it may be applied to breast cancer tumors.

  • Reply to

    partnership

    by kajalnp Feb 1, 2016 11:55 AM
    trendbase trendbase Feb 1, 2016 9:40 PM Flag

    Who would want to partner with Agenus in the Bay area anyway ?

  • I wonder if Agenus has any rights to Recepta's antibody pieline ?

  • trendbase trendbase Jan 31, 2016 11:49 AM Flag

    Not even close.
    Recepta has the South American rights for CTLA-4 from a previous R&D collaboration with 4-AB AG.

    4-ANTIBODY AG AND THE LUDWIG INSTITUTE EXPAND ONCOLOGY ANTIBODY R&D PROGRAM WITH THREE NEW TARGETS
    Jan 29, 2013 | 4:15 pm

  • 2:33 am, Thu Jan 14, 2016.
    By NAPS,
    North American Precis Syndicate
    (NAPSI)—For the more than 680,000 Americans living with a brain tumor, there is a revolutionary research effort under way at the Precision Medicine Initiative Against Brain Cancer headed by Dr. Chirag Patil at Cedars-Sinai in Los Angeles, to look at ways of using precision science to tailor personalized treatments for individuals with malignant brain tumors.
    Brain Cancer Meets Precision Science
    Brain cancer continues to be among the hardest of diseases to treat. Until now, most medical treatments for the most common, aggressive and lethal form of brain cancer, glioblastoma multiforme, which affects more than 138,000 Americans yearly, have been designed for the average patient. Given that every cancer is genetically unique, this “one-size-fits-all” drug treatment has not worked for brain cancer and for most solid cancers. Unfortunately, today’s standard-of-care, which includes surgical removal, radiation therapy, and chemotherapy, has only modest benefits with patients living on average 15 months after diagnosis.
    “Precision Medicine, an innovative approach that takes into account individual differences in people’s genes, environments and lifestyles, only works when we apply ‘Precision Science’ to the effort,” notes Dr. Chirag Patil, M.D., Neurosurgeon & Program Director at Cedars-Sinai Medical Center. “If we want to treat cancer more effectively, we need a novel approach to cancer care. In our program, we use tumor genomics and precision science to build a holistic mathematical model of cancer that then can be used to develop new, personalized cancer treatments. Right now, we’re focused on the most common type of brain cancer, but are developing a unique scientific process that could tackle ANY type of cancer.”

    Sounds familiar.

  • Reply to

    IND partner with INCY?

    by tdacton Jan 11, 2016 9:52 AM
    trendbase trendbase Jan 12, 2016 4:51 PM Flag

    INCAGN1876, an anti-GITR agonist antibody that is part of the ongoing discovery alliance with Agenus, Inc, is expected to enter clinical trials for the treatment of patients with advanced cancer during the first half of 2016. Incyte’s alliance with Agenus has recently been expanded to include a total of 7 therapeutic targets, with options for additional expansion.

  • Reply to

    F-K Filing Deadlines.

    by trendbase Dec 22, 2015 6:27 PM
    trendbase trendbase Jan 11, 2016 7:08 AM Flag

    FOLLOWING RECEIPT OF IND BY THE FDA
    The IND will be routed to the appropriate division for review. A letter of acknowledgment will be sent to the sponsor investigator.This letter provides the assigned IND number, date received, and the name and telephone number of the FDA project manager to whom questions about the application and further correspondence should be directed. The IND becomes effective 30 days after the stated FDA receipt date unless the FDA sends notification otherwise. The FDA generally does not send a letter notifying the sponsor-investigator of approval.Studies may begin after the 30-day interval, if the FDA does not notify the investigator otherwise. If the FDA requests further information or clarification, the 30-day window is not affected unless the FDA gives an indication that the study is placed on a complete or partial clinical hold. A partial hold will allow a specific part of the study to begin while the other part cannot bestarted. A clinical hold explicitly means that the study may not begin.

  • Reply to

    I b defeated

    by ship_wreck_matey Jan 7, 2016 9:43 AM
    trendbase trendbase Jan 8, 2016 3:48 AM Flag

    3:40 seconds into the Webcast.

  • Reply to

    I b defeated

    by ship_wreck_matey Jan 7, 2016 9:43 AM
    trendbase trendbase Jan 8, 2016 3:32 AM Flag

    Oppenheimer 26th Annual Healthcare Conference Webcast.

  • Reply to

    I b defeated

    by ship_wreck_matey Jan 7, 2016 9:43 AM
    trendbase trendbase Jan 7, 2016 9:22 PM Flag

    Yes. It's true.

  • trendbase by trendbase Jan 4, 2016 1:52 PM Flag

    35 million to go.

  • Reply to

    CEO selling is positive??

    by my3dingos Dec 31, 2015 11:50 AM
    trendbase trendbase Dec 31, 2015 4:34 PM Flag

    Not good. He just knows something. I'm very disappointed. Tax planning ?
    You can read the following article to get a better understanding.
    How alarming is it when CEOs start selling their shares? by Jon Hansen

  • Oh where, oh where, can they be..........

    Sentiment: Strong Buy

  • Reply to

    Garo wants all existing in immunoterapy

    by jlemon09 Dec 26, 2015 4:47 PM
    trendbase trendbase Dec 27, 2015 5:15 PM Flag

    We also have a cocktail of undisclosed phospeptide tumor antigens in Phase 1 for Melanoma.

    Sentiment: Strong Buy

  • trendbase trendbase Dec 25, 2015 9:08 PM Flag

    Patent WO2011149909A2 - Class i mhc phosphopeptides ...

    Sentiment: Strong Buy

  • Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA
    Abstract

    Background: There is a pressing need for novel immunotherapeutic targets in colorectal cancer (CRC). Memory CD8+ T cell infiltration is now well established as a key prognostic indicator in CRC, and it is known that these tumor infiltrating lymphocytes (TILs) are specifically targeting and killing tumor cells. However, the epitopes that these TILs use to identify cancer cells have not been determined. This has limited the use of immunotherapies in CRC, despite their efficacy in other cancer types. Recently, phosphopeptides have emerged as strong candidates for tumor-specific epitopes, since dysregulation of signaling in cancers leads to aberrant protein phosphorylation. Here, we identify CRC-associated phosphopeptides and assess the tumor-resident immunity against these novel epitopes.

    Methods: We compared tumor and healthy tissue from CRC patients, to identify tumor-specific MHC class-I associated phosphopeptides. The tissues were lysed, the MHC class-I complexes affinity purified, and the bound peptides eluted. Phosphopeptides were enriched using immobilized metal affinity chromatography, and characterized using mass spectrometry. TILs, from the same tumors, were extracted and expanded, and their responses to the phosphopeptides assessed using multiplexed intracellular cytokine staining. Cytolytic activity was observed by staining for surface mobilization of CD107a. Healthy donor responses were quantified using interferon-γ ELISpot, and functionality assessed using a europium release killing assay.

    Results: We have identified 125 tumor-associated MHC class-I phosphopeptides from CRC, with different HLA-restrictions. There were, on average, 3.5 times more different phosphopeptides identified on cancer than healthy tissues, at 6.7-fold higher levels. Many of these novel epitopes are attributable to signaling events in well-defined cancer pathways and are therefore markers of malignancy

    Sentiment: Strong Buy

  • Reply to

    What happened with the HerpV program?

    by swissquotee Dec 25, 2015 2:49 AM
    trendbase trendbase Dec 25, 2015 11:08 AM Flag

    Cut out the con man routine. It's Christmas day. It's not righteous.

  • trendbase by trendbase Dec 22, 2015 6:27 PM Flag

    Except as described below, a Form 8-K must be
    filed within four business days after the
    occurrence of a reportable event. For purposes
    of counting, day one is the first business day
    after the day on which the reportable event
    occurs.
    The following table indicates the day of the
    week on which Form 8-K filings will generally
    be due under the standard four-business-day
    deadline:
    Date of Event
    Due Date
    (assuming no
    holidays)
    Sunday Thursday
    Monday Friday
    Tuesday Monday
    Wednesday Tuesday
    Thursday Wednesday
    Friday Thursday
    Saturday Thursday

    Sentiment: Strong Buy

  • trendbase trendbase Dec 21, 2015 10:10 PM Flag

    You are correct. 30 days.

    Sentiment: Strong Buy

  • trendbase trendbase Dec 21, 2015 7:12 AM Flag

    Higher PD-L1 Expression Associated With Worse Glioblastoma Survival

    News | November 23, 2015 | SNO 2015, Brain Tumors
    By Bryant Furlow
    Lomustine/Bevacizumab Fails to Improve Survival in Recurrent Glioblastoma
    Adding PCV to RT Shows Survival Benefit in IDH1 R132H-Positive Glioma
    Markers Could Predict Risk of Brain Metastasis in Breast Cancer Patients
    ReACT: Vaccine Improves Long-Term Survival in Recurrent EGFRvIII-Positive Glioblastoma
    Does Pregnancy Stimulate Glioma Progression?
    Dendritic Cell Immunotherapy Promising in HLA-A2-Positive Glioblastoma
    Gene-Mediated Cytotoxic Immunotherapy Improves Survival in Newly Diagnosed Glioma
    Higher PD-L1 Expression Associated With Worse Glioblastoma Survival
    Innovative GBM Trial Could Hasten Development of New Treatments
    BRAF/MEK Inhibitors Show Promise in Pediatric Astrocytoma
    Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes, according to results presented at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology, held November 19-22 in San Antonio, Texas.

    “PD-L1 expression in [glioblastoma] is frequent but is largely confined to a minority subpopulation—similar to other malignancies that have been profiled for PD-L1 expression,” reported lead study author Edjah K. Nduom, MD, of the MD Anderson Cancer Center in Houston, and coauthors, in a poster presentation. “Higher expression of PD-L1 is correlated with worse outcome, and proper stratification of PD-L1–positive and negative patients may become an important criterion for high-quality immunotherapeutic trials in [glioblastoma]. Expression of PD-L1 on infiltrating lymphocytes also suggests that a unique immunosuppressive pathway may operate in [glioblastoma].”

    Immune checkpoint-inhibitor therapies that target immune response–inhibiting CTLA-4 and PD-1/PD-L1 can facilitate glioblastoma tumor regression and phase II clinical trials are ongoing, Dr. Nduom’s team noted. Bu

NBS
2.250.00(0.00%)Jun 5 3:59 PMEDT